Quantcast
Home > Quotes > VRCA

Verrica Pharmaceuticals Inc. Common Stock (VRCA) Quote & Summary Data

VRCA 
$10.01
*  
0.09
0.91%
Get VRCA Alerts
*Delayed - data as of Apr. 24, 2019  -  Find a broker to begin trading VRCA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    VRCA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 7.19 / $ 25
Today's High / Low
$ 10.1906 / $ 9.36
Share Volume
21,162
50 Day Avg. Daily Volume
62,974
Previous Close
$ 9.92
52 Week High / Low
$ 23.29 / $ 6.44
Market Cap
257,329,633
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
21,162
50 Day Avg. Daily Volume:
62,974

Trading Range

The current last sale of $10.01 is 55.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 10.1906 $ 23.29
 Low: $ 9.36 $ 6.44

Company Description (as filed with the SEC)

We are a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases. Our lead product candidate, VP-102, is a proprietary drug-device combination of our novel topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through our single-use precision applicator. We are initially developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. There are currently no products approved by the U.S. Food and Drug Administration, or FDA, nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology.  ... More ...  



Risk Grade

Where does VRCA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 9.88
Open Date:
Apr. 24, 2019
Close Price:
$ 10.01
Close Date:
Apr. 24, 2019


Consensus Recommendation

Analyst Info